BofA analyst Alec Stranahan lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $21 and keeps a Buy rating on the shares. Following the Q1 report, the firm updated its model with greater collaboration revenue expectations for 2026 and a higher share count and cash position, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: